CATALYST PHARMA PTR (NASDAQ:CPRX)
0.70
+0.01 (1.45%)
| CATALYST PHARMA PTR (NASDAQ:CPRX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $0.69 | 52 Week High | $2.84 | ||
| Open | $0.68 | 52 Week Low | $0.39 | ||
| Day High | $0.79 | P/E | N/A | ||
| Day Low | $0.68 | EPS | $-0.71 | ||
| Volume | 48,724 | ||||
| More CPRX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ASTI | 3 | BLDR | 2 |
| XRTX | 2 | ACAD | 2 |
| NVAX | 2 | BIOF | 2 |
| AIG | 2 | CHTP | 2 |
| CRAI | 2 | CRMT | 2 |
| ASTI | 2 | EDAP | 2 |
Entities who have mentioned CPRX
- Merriman Curhan Ford | View Related Stories »
- Bakken Formation | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Credit Suisse | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- Morgan Keegan & Company | View Related Stories »
- Bankruptcy | View Related Stories »
- Deutsche Bank | View Related Stories »
- JPMorgan | View Related Stories »
- Sanford C. Bernstein | View Related Stories »
- Warburg Pincus | View Related Stories »
- Banc of America | View Related Stories »
- S3 | View Related Stories »
- Roth Capital | View Related Stories »
- Needham & Co | View Related Stories »
- 13G | View Related Stories »
- UBS | View Related Stories »
- Morgan Stanley | View Related Stories »
- Citi | View Related Stories »
- Barclays | View Related Stories »
- After-Hours Movers | View Related Stories »
View All Major News StreetInsider.com Major News for CPRX
- Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
- Catalyst Pharmaceutical (CPRX) Surges On Plans to Continue Development of Addiction Treatment
- Catalyst Pharmaceutical (CPRX) Said CPP-109 Trial Did Not Demonstrate Statistical Significance
View All ReportsStreetInsider.com Reports on CPRX
- Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
- Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
- Catalyst (CPRX) Announces Organizational Changes and CEO McEnany's Term Extension
- Hapoalim Securities Upgrades Catalyst Pharmaceutical (CPRX) to Hold
- Morning Movers 10/05: DEPO, AVII, OPTV, CRXX, UCTT, CPRX Higher; FOLD, FTBK, SGEN, SCLN, REED Lower
View All Press ReleasesCompany Press Releases on CPRX
- Catalyst Receives Guidance from Nasdaq Regarding Minimum Bid Price Requirement
- Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
- U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
- Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executive's Employment Agreement
- Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
StreetInsider Reports on CPRX by Category
View All FilingsSEC Filings on CPRX
- Form 4 Catalyst Pharmaceutical For: Nov 18 Filed by: GRANDE ALICIA
- Form 4 Catalyst Pharmaceutical For: Nov 17 Filed by: WALLACE MILTON J
- Form 4 Catalyst Pharmaceutical For: Nov 17 Filed by: COELHO PHILIP H
- Form 4 Catalyst Pharmaceutical For: Nov 17 Filed by: O'Keeffe Charles B
- Form 4 Catalyst Pharmaceutical For: Nov 16 Filed by: MCENANY PATRICK J
Comments on CPRX
No comments are currently available.
